CE: Managing Chronic Immune Thrombocytopenia: Opportunities for Oncology Pharmacists to Optimize Patient Care

Publication
Article
Pharmacy Practice in Focus: OncologyNovember 2020
Volume 2
Issue 5

This activity is supported by educational grants from Dova Pharmaceuticals, INC. and Cure Media Group.

This activity is supported by educational grants from Dova Pharmaceuticals, INC. and Cure Media Group.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Examine the epidemiology, pathophysiology, diagnosis, and impact of chronic immune thrombocytopenia (ITP) among patients with cancer
  • Analyze the latest efficacy and safety data as well as dosing and administration of current pharmacologic treatments of chronic ITP
  • Illustrate the role of the oncology pharmacist in the management of chronic ITP

FACULTY:

Julianne O. Darling, PharmD, BCOP

Outpatient Oncology Clinical Pharmacist , Indiana University Simon Cancer Center, Indianapolis, Indiana

TARGET AUDIENCE: Pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: October 30, 2020

EXPIRATION DATE: November 30, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.

Related Videos
Image Credit: © Anastasiia - stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
breast cancer treatment/Image Credit: © Siam - stock.adobe.com
Image Credit: © Dragana Gordic - stock.adobe.com
small cell lung cancer treatment/Image Credit: © CraftyImago - stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
car t cell therapy multiple myeloma/Image Credit: © Lusi_mila - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.